Abstract
Background: Many genetic variants and multiple environmental factors increase risk for schizophrenia (SZ). SZ-associated genetic variants and environmental risk factors have been associated with altered DNA methylation (DNAm), the addition of a methyl group to a cytosine in DNA. DNAm changes, acting through effects on gene expression, represent one potential mechanism by which genetic and environmental factors confer risk for SZ and alter neurobiology. Methods: We investigated the hypothesis that DNAm in superior temporal gyrus (STG) is altered in SZ. We measured genome-wide DNAm in postmortem STG from 44 SZ subjects and 44 non-psychiatric comparison (NPC) subjects using Illumina Infinium MethylationEPIC BeadChip microarrays. We applied tensor composition analysis to extract cell type-specific DNAm signals. Results: We found that DNAm levels differed between SZ and NPC subjects at 242 sites, and 44 regions comprised of two or more sites, with a false discovery rate cutoff of q=0.1. We determined differential methylation at nine of the individual sites were driven by neuron-specific DNAm alterations. Glia-specific DNAm alterations drove the differences at two sites. Notably, we identied SZ-associated differential methylation within within mitotic arrest deficient 1-like 1 (MAD1L1), a gene strongly associated with SZ through genome-wide association studies. Conclusions: This study adds to a growing number of studies that implicate DNAm, and epigenetic pathways more generally, in SZ. Our findings suggest differential methylation may contribute to STG dysfunction in SZ. Future studies to identify the mechanisms by which altered DNAm, especially within MAD1L1, contributes to SZ neurobiology are warranted.
Competing Interest Statement
This work was supported by NIH Grants K23 MH112798 (BCM) and R01 MH071533, MH116046, and AG027224 (RAS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, or the United States Government. DAL currently receives investigator-initiated research support from Pfizer and Merck. All the other authors declare no competing interests.
Funding Statement
This work was supported by NIH Grants K23 MH112798 (BCM) and R01 MH071533, MH116046, and AG027224 (RAS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, or the United States Government. DAL currently receives investigator-initiated research support from Pfizer and Merck. All the other authors declare no competing interests.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures were approved by the University of Pittsburgh Committee for the Oversight of Research and Clinical Training Involving Decedents and the Institutional Review Board for Biomedical Research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available for download from Gene Expression Omnibus (GEO; GSE144910)
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144910
